Alright, by popular request from like one person and to amuse basically just myself… here’s #MetGala 2024 outfits as medical specialties for a third year in a row

Just launched: Cancer Luminaries, a podcast discussing the past, present and future of cancer research in honor of our 50 yrs of NCI designation. Our first two episodes feature Todd Golub and Otis Brawley. ow.ly/xw9f50RpgtL #UChiCancer50 Johns Hopkins Kimmel Cancer Center Broad Institute

T-DXd is the premier ADC for the treatment of pts with HER2+ MBC BrMs.

The analysis underscores the pressing need to investigate T-DXd in HER2-low BrMs, active HER2+ BrMs across solid tumors, and LMD.
We suggest default inclusion of pts with BrMs into clinical trials of ADCs.

In lockstep with the ASCO Presidential Theme ASCOPres - Palliative Care is on the stage as a PLENARY at this year's Annual Meeting

This kind of research matters - has reach, clinical practice, and policy implications

meetings.asco.org/abstracts-pres…

Truly groundbreaking work that turned a failed chemotherapy in one of the most active anticancer drugs ever developed

This week we lost swaggsheila, a fierce advocate for the entire metastatic community. To know her was to love her: her smile lit up the room, and her positivity was felt throughout. Sheila was a GRASP mentor since our first in-person at SABCS2019, and her loss is felt deeply.

SNEAK PEEK 👀 Get a behind-the-scenes preview of the brand-new UChicago Medicine Crown Point multispecialty care center, which opens April 29. Dr. Blase Polite, physician-in-chief of Northwest Indiana, shares what this means for cancer patients that live in the community.

Fantastic work looking at #tucatinib activity post #TDXd for #HER -2+ #bcsm . These real world looks at a drug's activity when sequencing is altered/new drugs are approved is important!

jamanetwork.com/journals/jaman…

In a Review now online, Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏, Aakash Desai, MD, MPH, Maryam Lustberg MD MPH and Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 explain the most common acute toxicities in patients with cancer receiving chemotherapy and discuss management options: nature.com/articles/s4157…

The OXEL trial, led by Filipa Lynce, MD, FASCO, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant nivo/cape were well tolerated, increased peripheral immune score & led to numerically improved 2y iDFS (91%) vs nivo (47%) or cape alone (53%). nature.com/articles/s4146…

🎉 Along with Conquer Cancer, the ASCO Foundation, we congratulate the recipients of our 2024 Special Awards! ➡️ brnw.ch/21wI5Wc #ASCO24

We have a great agenda. Please join us if you can!

Every female physician felt this in her core.

Love it. So fun.

Exciting news!
UChicago Medicine is bringing specialized medical care to cancer patients in Northwest Indiana with a new center in Crown Point. The cancer services include infusion therapy, radiation and medical and surgical oncology.
UChicagoCancerCenter
ow.ly/YCaL50QNOBV

Featuring the most clinically relevant science and hottest research topics in oncology, you’ll find a world of inspiration at the 2024 ASCO Annual Meeting.

📢 The President's Cancer Panel has released their report on the #NationalCancerPlan , which highlights five priority areas:
▪️ Investment in research
▪️ Insurance coverage
▪️ Workforce
▪️ Community engagement
▪️ Data sharing/integration

👉 prescancerpanel.cancer.gov/ncp/reports

The UChicago Breast Cancer Program is excited organize a Stat of the Science Summit on March 21, 2024 in downtown Chicago. Please join us! #bcsm

An important new treatment option now able to be offered here at UChicago Medicine UChicagoCancerCenter University of Chicago Hematology/Oncology!!!

📣 Exciting news!
UChicagoCancerCenter launched a new center today 'The Center to Eliminate Cancer Inequity (CinEQUITY)' with a goal to create solutions for eliminating disparities that can be implemented by communities, healthcare systems and policymakers. #EqualHealthForAll